Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.
暂无分享,去创建一个
H. Kantarjian | J. Lipton | H. Khoury | A. Hochhaus | F. Nicolini | S. Corm | Dan Jones | A. Craig | E. Humphriss | J. Cortes-Franco | A. Benichou